HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting - Episode 2

SABCS 2021: Updates in Metastatic Breast Cancer

, , ,

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.

Data from the following clinical trials are discussed:

  • GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with HER2–positive metastatic breast cancer: subgroup analyses from the randomized phase 3 study DESTINYBreast03
  • GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial pyrotinib vs lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer
  • GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor (HR)–positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: latest updates from the SUMMIT trial
  • P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2+ metastatic breast cancer: results from a phase I study
  • P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy for HER2+ breast cancer: results from a phase 1 study
  • PD8-07: Evaluation of tucatinib + paclitaxel + pertuzumab + trastuzumab followed by AC (doxorubicin hydrochloride, cyclophosphamide) in high-risk HER2+ stage II/III breast cancer: results from the I-SPY2 trial